Literature DB >> 9894874

Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis.

J Burns1, B Bartholomew, S Lobo.   

Abstract

Myelin antigen-reactive T cells have been implicated in the pathogenesis of multiple sclerosis (MS). Myelin-reactive T cells can be isolated from control subjects as well as individuals who have MS. Experimental models of MS indicate that recently stimulated, myelin-reactive T cells have greater encephalitogenic potential than resting T cells. Activation induces changes in T-cell surface antigens that may distinguish previously stimulated, memory T cells from naive T cells. Therefore, we examined 108 myelin basic protein (MBP)-reactive T-cell lines from 7 MS and 8 control subjects to determine whether MBP-reactive T cells originated in the memory T-cell subset or in the naive subset. Isotypes of CD45 were used that designate memory or naive T cells. In subjects having MS, 84% of the MBP-reactive T cells resided in the memory T-cell subset. However, in control subjects, only 13% of MBP-specific T cells originated from the memory T-cell subset. This result suggests that a substantial proportion of MBP-reactive T cells from some individuals with MS have been previously activated in vivo. This difference provides additional support for the hypothesis that myelin antigen-specific T cells are involved in the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9894874

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

Review 1.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 2.  The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Authors:  Andrew P Robinson; Christopher T Harp; Avertano Noronha; Stephen D Miller
Journal:  Handb Clin Neurol       Date:  2014

3.  IL-23R-activated STAT3/STAT4 is essential for Th1/Th17-mediated CNS autoimmunity.

Authors:  Priscilla W Lee; Alan J Smith; Yuhong Yang; Amanda J Selhorst; Yue Liu; Michael K Racke; Amy E Lovett-Racke
Journal:  JCI Insight       Date:  2017-09-07

4.  Novel small molecule IL-6 inhibitor suppresses autoreactive Th17 development and promotes Treg development.

Authors:  S I Aqel; E E Kraus; N Jena; V Kumari; M C Granitto; L Mao; M F Farinas; E Y Zhao; G Perottino; W Pei; A E Lovett-Racke; M K Racke; J R Fuchs; C Li; Y Yang
Journal:  Clin Exp Immunol       Date:  2019-01-24       Impact factor: 4.330

Review 5.  Effector T Cells in Multiple Sclerosis.

Authors:  Belinda J Kaskow; Clare Baecher-Allan
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

6.  Differential responses of CD45+ve T-cell subsets to MBP in multiple sclerosis.

Authors:  M Ponsford; G Mazza; J Coad; M J Campbell; J Zajicek; D C Wraith
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

7.  Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.

Authors:  Y M Huang; N Stoyanova; Y P Jin; N Teleshova; Y Hussien; B G Xiao; S Fredrikson; H Link
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

Review 8.  Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?

Authors:  Amy E Lovett-Racke; Yuhong Yang; Michael K Racke
Journal:  Biochim Biophys Acta       Date:  2010-06-18

Review 9.  Autoimmune T cell responses in the central nervous system.

Authors:  Joan Goverman
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

10.  T-bet is essential for encephalitogenicity of both Th1 and Th17 cells.

Authors:  Yuhong Yang; Jeffrey Weiner; Yue Liu; Alan J Smith; David J Huss; Ryan Winger; Haiyan Peng; Petra D Cravens; Michael K Racke; Amy E Lovett-Racke
Journal:  J Exp Med       Date:  2009-06-22       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.